NRAS and neoplasm: Driver alterations and mutational burden are also related; tumours driven by BRAFV600E mutations tend to have fewer somatic mutations than tumours bearing other, possibly less potent, alterations such as loss of NF1 and activation of NRAS, KIT and BRAF non‐V600E 1.